(Q35550741)

8 August 2017

title

Rifaximin Is Effective for the Treatment of Clostridium difficile-Associated Diarrhea: Results of an Open-Label Pilot Study (English)

1 reference

8 August 2017

0 references

Clostridium difficile

0 references

1

David T Rubin

1 reference

8 August 2017

Sunana Sohi

2

1 reference

8 August 2017

Matthew Glathar

3

1 reference

8 August 2017

Tojo Thomas

4

1 reference

8 August 2017

Nicole Yadron

5

1 reference

8 August 2017

Bonnie L Surma

6

1 reference

8 August 2017

publication date

9 November 2011

1 reference

Gastroenterology research and practice

8 August 2017

published in

1 reference

8 August 2017

volume

2011

1 reference

8 August 2017

page(s)

106978

1 reference

Creative Commons Attribution 3.0 Unported

8 August 2017

copyright license

start time

1 January 2011

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216319

Clostridium difficile: recent epidemiologic findings and advances in therapy

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216319

In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216319

Implications of the changing face of Clostridium difficile disease for health care practitioners

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216319

Clinical features of Clostridium difficile-associated infections and molecular characterization of strains: results of a retrospective study, 2000-2004.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216319

Current and future developments in travelers' diarrhea therapy

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216319

Clostridium difficile-associated diarrhea: resurgence with a vengeance.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216319

Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216319

An epidemic, toxin gene-variant strain of Clostridium difficile

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216319

A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216319

Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216319

Rifaximin: a nonabsorbed oral antibiotic.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216319

Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216319

Clostridium difficile--Associated diarrhea: A review

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216319

In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216319

Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. American College of Gastroenterology, Practice Parameters Committee

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216319

Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216319

Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3216319

A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use.

12 July 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F106978

Increasing prevalence and severity of Clostridium difficile colitis in hospitalized patients in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F106978

Clostridium difficile colitis: factors influencing treatment failure and relapse--a prospective evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F106978

Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F106978

Efficacy of rifaximin and vancomycin combination therapy in a patient with refractory Clostridium difficile-associated diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F106978

Emergence and Control of Fluoroquinolone-Resistant, Toxin A–Negative, Toxin B–Positive Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F106978

Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F106978

Interruption of Recurrent Clostridium difficile-Associated Diarrhea Episodes by Serial Therapy with Vancomycin and Rifaximin

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22114587

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1155/2011/106978

1 reference

8 August 2017

1 reference

8 August 2017

1 reference